These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 8948025)

  • 1. Effects of pegylated recombinant human megakaryocyte growth and development factor on thrombocytopenia induced by a new myelosuppressive chemotherapy regimen in mice.
    Akahori H; Shibuya K; Ozai M; Ida M; Kabaya K; Kato T; Miyazaki H
    Stem Cells; 1996 Nov; 14(6):678-89. PubMed ID: 8948025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo effects of pegylated recombinant human megakaryocyte growth and development factor on hematopoiesis in normal mice.
    Kabaya K; Akahori H; Shibuya K; Nitta Y; Ida M; Kusaka M; Kato T; Miyazaki H
    Stem Cells; 1996 Nov; 14(6):651-60. PubMed ID: 8948023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of thrombocytopenia following bone marrow transplantation by pegylated recombinant human megakaryocyte growth and development factor in mice.
    Kabaya K; Shibuya K; Torii Y; Nitta Y; Ida M; Akahori H; Kato T; Kusaka M; Miyazaki H
    Bone Marrow Transplant; 1996 Dec; 18(6):1035-41. PubMed ID: 8971370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic effects of pegylated recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor on mobilization of hematopoietic progenitor and stem cells with long-term repopulating ability into peripheral blood in mice.
    Honda K; Takenaka K; Shinagawa K; Ishimaru F; Ikeda K; Niiya K; Harada M
    Bone Marrow Transplant; 2001 Aug; 28(4):329-34. PubMed ID: 11571503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombopoietin: biology and clinical potentials.
    Miyazaki H; Kato T
    Int J Hematol; 1999 Dec; 70(4):216-25. PubMed ID: 10643146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic effects of pegylated recombinant human megakaryocyte growth and development factor in combination with recombinant murine granulocyte colony-stimulating factor in a murine model of myelosuppression.
    Coleman D; Fairchild D; Schindler-Horvat J; Munyakazi L; Neumann TA
    Toxicol Sci; 1998 Sep; 45(1):77-87. PubMed ID: 9848114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of thrombocytopenia and neutropenia in a nonhuman primate model of marrow suppressive chemotherapy by combining pegylated recombinant human megakaryocyte growth and development factor and recombinant human granulocyte colony-stimulating factor.
    Harker LA; Marzec UM; Kelly AB; Cheung E; Tomer A; Nichol JL; Hanson SR; Stead RB
    Blood; 1997 Jan; 89(1):155-65. PubMed ID: 8978288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hematopoietic recovery following autologous bone marrow transplantation in a nonhuman primate: effect of variation in treatment schedule with PEG-rHuMGDF.
    Farese AM; MacVittie TJ; Roskos L; Stead RB
    Stem Cells; 2003; 21(1):79-89. PubMed ID: 12529554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation.
    Bolwell B; Vredenburgh J; Overmoyer B; Gilbert C; Chap L; Menchaca DM; Cruickshank S; Glaspy J
    Bone Marrow Transplant; 2000 Jul; 26(2):141-5. PubMed ID: 10918423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Further examination of various administration protocols of pegylated recombinant human megakaryocyte growth and development factor on thrombocytopenia in myelosuppressed mice.
    Akahori H; Ozai M; Ida M; Shibuya K; Kato T; Miyazaki H
    Ther Apher; 1998 Feb; 2(1):58-64. PubMed ID: 10227790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multilineage hematopoietic recovery by a single injection of pegylated recombinant human megakaryocyte growth and development factor in myelosuppressed mice.
    Shibuya K; Akahori H; Takahashi K; Tahara E; Kato T; Miyazaki H
    Blood; 1998 Jan; 91(1):37-45. PubMed ID: 9414267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prior and concurrent administration of recombinant human megakaryocyte growth and development factor in patients receiving consolidation chemotherapy for de novo acute myeloid leukemia--a randomized, placebo-controlled, double-blind safety and efficacy study.
    Geissler K; Yin JA; Ganser A; Sanz MA; Szer J; Raghavachar A; Hoelzer D; Martinez C; Taylor K; Kanz L; To LB; Archimbaud E
    Ann Hematol; 2003 Nov; 82(11):677-83. PubMed ID: 14530872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiologic role of TPO in thrombopoiesis.
    Miyazaki H
    Stem Cells; 1996; 14 Suppl 1():133-8. PubMed ID: 11012213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PEG-rHuMGDF ameliorates thrombocytopenia in carboplatin-treated rats without inducing myelofibrosis.
    Ide Y; Harada K; Imai A; Yanagida M
    Int J Hematol; 1999 Aug; 70(2):91-6. PubMed ID: 10497847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An analysis of the effects of combined treatment with rmGM-CSF and PEG-rHuMGDF in murine bone marrow transplant recipients.
    Molineux G; Hartley C; McElroy P; McCrea C; Kerzic P; McNiece I
    Stem Cells; 1997; 15(1):43-9. PubMed ID: 9007221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human ligand for MPL, megakaryocyte growth and development factor (MGDF), stimulates thrombopoiesis in vivo in normal and myelosuppressed baboons.
    Andrews RG; Winkler A; Myerson D; Briddell RA; Knitter GH; McNiece IK; Hunt P
    Stem Cells; 1996 Nov; 14(6):661-77. PubMed ID: 8948024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early Australian clinical studies with pegylated recombinant human megakaryocyte growth and development factor.
    Basser RL
    Stem Cells; 1998; 16 Suppl 2():225-9. PubMed ID: 11012194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Megakaryocyte growth and development factor accelerates platelet recovery in peripheral blood progenitor cell transplant recipients.
    Molineux G; Hartley C; McElroy P; McCrea C; McNiece IK
    Blood; 1996 Jul; 88(1):366-76. PubMed ID: 8704197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer.
    Basser RL; Underhill C; Davis I; Green MD; Cebon J; Zalcberg J; MacMillan J; Cohen B; Marty J; Fox RM; Begley CG
    J Clin Oncol; 2000 Aug; 18(15):2852-61. PubMed ID: 10920133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombopoietin accelerates platelet, red blood cell, and neutrophil recovery in myelosuppressed mice.
    Grossmann A; Lenox J; Ren HP; Humes JM; Forstrom JW; Kaushansky K; Sprugel KH
    Exp Hematol; 1996 Aug; 24(10):1238-46. PubMed ID: 8765500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.